ReviewACS omega2026
Interfacial Engineering of Biosensors for Bloodstream Infection Diagnosis.
Review in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bloodstream infection (BSI) is a life-threatening systemic disease with rapid onset and high mortality, which calls for rapid and accurate pathogen detection for precision medical care. Conventional diagnostic methods, including blood culture, molecular assays, and mass spectrometry, remain limited by long turnaround time, matrix interference, high cost, or insufficient point-of-care applicability. Biosensor interface engineering provides a promising route to improve pathogen capture, antifouling capability, and signal transduction in complex blood matrices. In this review, we summarize recent advances in biosensing interfaces for BSI diagnosis from three interconnected perspectives: signal transduction strategies, biorecognition elements, and antifouling surface designs. We further discuss direct sensing of intact bacterial cells and indirect sensing of bacterial or host-response biomarkers. Finally, remaining challenges in whole-blood compatibility, device integration, standardization, and clinical validation are highlighted to guide the development of next-generation point-of-care diagnostic platforms.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.